BEIJING – Multinational antibody specialist Hifibio Therapeutics Inc. said it closed a $67 million series C financing round to advance its drug candidates for cancer and autoimmune disorders.

DUBLIN – Gyroscope Therapeutics Ltd. raised £50.4 million (US$60.5 million) to further development of GT-005, its clinical-stage gene therapy for treating dry age-related macular degeneration (AMD), and to advance a second-generation of the subretinal delivery system it gained through its recent merger with Orbit Biomedical Ltd.

LONDON – Achilles Therapeutics Ltd. closed a £100 million (US$120 million) series B round to fund two proof-of-concept studies of its next-generation T-cell immunotherapy in solid tumors, and to build a commercial-scale, fully automated facility for manufacturing the personalized product.

SEOUL – After a decade of steady increases, venture capital (VC) investments in South Korea's biotech sector are more active. But for the country's strategic financial plan to be sustainable, it will have to further strengthen its science capabilities, according to experts at the Korea Bio Investment Conference (KBIC) last week in Seoul.

PERTH, Australia – Telix Pharmaceuticals Ltd. raised AU$40 million as it prepares regulatory packages and commercial strategies in Europe, the U.S. and Australia.

Tetra Bio-Pharma Inc., of Ottawa, Ontario, said it intends to complete a non-brokered private placement offering, where some of the corporation's directors, officers, consultants and employees, as well of certain of their associates, will purchase an aggregate of 870,000 units at CA0.30 each for aggregate gross proceeds of CA$261,000 (US$197,750). 

Foamix Pharmaceuticals Ltd., an Israeli specialty pharma developing foam-based formulations of minocycline for moderate-to-severe acne and rosacea, has secured up to $64 million in financing from Perceptive Advisors and Orbimed, its two largest shareholders. The funds, comprised of loans and proceeds of a registered direct offering, are expected to support potential commercial launches for FMX-101 and FMX-103, pending FDA approval, the company said.

Ziopharm Oncology Inc., of Boston, said it entered into an agreement with existing investors for the exercise of previously issued warrants to purchase common stock in a private placement, being led by existing stockholder, MSD Partners LP, that is expected to result in gross proceeds of approximately $45 million. 

PERTH, Australia – Following positive results across three different oncology clinical trial programs with its lead candidate, Veyonda, Sydney-based Noxopharm Pty Ltd. has secured a AU$26 million (US$18 million) funding facility from U.S. investors leading up to a proposed Nasdaq listing.

Exopharm Ltd., of Melbourne, Australia, said it finalized an AU$4.44 million (US$3.03 million) share placement to new institutional and sophisticated investors.